Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16450604 | 0.89 | LOX (0.45) | HDAC6LOXLOXL2HCRTR1HCRTR2 | |
| SCHEMBL17300714 | 0.86 | LOX (0.50) | HDAC6LRRK2LOXLOXL2ACACB | |
| SCHEMBL16217367 | 0.82 | ROCK1 (0.45) | LOXLOXL2SYKHCRTR1HCRTR2 | |
| SCHEMBL16217415 | 0.81 | LRRK2 (0.42) | LRRK2LOXLOXL2HCRTR1HCRTR2 | |
| SCHEMBL3401548 | 0.80 | HDAC6 (0.50) | HDAC6LRRK2LOXLOXL2ACACB | |
| SCHEMBL8277607 | 0.80 | HDAC6 (0.50) | HDAC6LRRK2LOXLOXL2ACACB | |
| SCHEMBL9967841 | 0.78 | LIPE (0.40) | HDAC6LRRK2SYKCNR2 | |
| SCHEMBL22965359 | 0.78 | LOX (0.38) | HDAC6LOXLOXL2HCRTR1HCRTR2 | |
| SCHEMBL19959032 | 0.78 | LOX (0.38) | HDAC6LOXLOXL2HCRTR1HCRTR2 | |
| SCHEMBL3323298 | 0.77 | HDAC6 (0.50) | HDAC6LRRK2LOXLOXL2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308121-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2021-10-07 | — | — | US | disclosed |
| US-10980794-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-11-14 | — | — | US | disclosed |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180098987-A1 | PRMT5 Inhibitors and Uses Thereof | Epizyme, Inc. (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180098987-A1 | PRMT5 Inhibitors and Uses Thereof | Epizyme, Inc. (US) | 2018-04-12 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170027935-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170027935-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-02-02 | — | — | US | disclosed |
| US-9365519-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150344434-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-09-10 | — | — | US | disclosed |
| US-8993555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308121-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HDAC6 125/4885LRRK2 325/4885LOX 2985/4885 |
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HDAC6 125/4885LRRK2 325/4885LOX 2985/4885 |
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HDAC6 177/4885LRRK2 287/4885LOX 3914/4885 |
| US-20180098987-A1 | PRMT5 Inhibitors and Uses Thereof | PRMT5, PRMT1, PRMT6 | HDAC6 125/4885LRRK2 325/4885LOX 2985/4885 |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HDAC6 179/4885LRRK2 362/4885LOX 3669/4885 |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | HDAC6 177/4885LRRK2 287/4885LOX 3914/4885 |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HDAC6 125/4885LRRK2 325/4885LOX 2985/4885 |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HDAC6 119/4885LRRK2 323/4885LOX 3025/4885 |
| US-20170027935-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HDAC6 125/4885LRRK2 325/4885LOX 2985/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HDAC6 177/4885LRRK2 287/4885LOX 3914/4885 |
| US-10980794-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT6 | HDAC6 125/4885LRRK2 325/4885LOX 2985/4885 |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HDAC6 179/4885LRRK2 362/4885LOX 3669/4885 |
| US-20150344434-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HDAC6 185/4885LRRK2 299/4885LOX 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.